Robertson Susan E, Roca Anna, Alonso Pedro, Simoes Eric A F, Kartasasmita Cissy B, Olaleye David O, Odaibo Georgina N, Collinson Mark, Venter Marietjie, Zhu Yuwei, Wright Peter F
Vaccines and Biologicals, Department of Immunization, World Health Organization, 1211 Geneva 27, Switzerland.
Bull World Health Organ. 2004 Dec;82(12):914-22. Epub 2005 Jan 5.
To assess the burden of respiratory syncytial virus (RSV)-associated lower respiratory infections (LRI) in children in four developing countries.
A WHO protocol for prospective population-based surveillance of acute respiratory infections in children aged less than 5 years was used at sites in Indonesia, Mozambique, Nigeria and South Africa. RSV antigen was identified by enzyme-linked immunosorbent assay performed on nasopharyngeal specimens from children meeting clinical case definitions.
Among children aged < 5 years, the incidence of RSV-associated LRI per 1000 child-years was 34 in Indonesia and 94 in Nigeria. The incidence of RSV-associated severe LRI per 1000 child-years was 5 in Mozambique, 10 in Indonesia, and 9 in South Africa. At all study sites, the majority of RSV cases occurred in infants.
These studies demonstrate that RSV contributes to a substantial but quite variable burden of LRI in children aged < 5 years in four developing countries. The possible explanations for this variation include social factors, such as family size and patterns of seeking health care; the proportion of children infected by human immunodeficiency syndrome (HIV); and differences in clinical definitions used for obtaining samples. The age distribution of cases indicates the need for an RSV vaccine that can protect children early in life.
评估四个发展中国家儿童呼吸道合胞病毒(RSV)相关下呼吸道感染(LRI)的负担。
在印度尼西亚、莫桑比克、尼日利亚和南非的研究点采用了世界卫生组织基于人群的5岁以下儿童急性呼吸道感染前瞻性监测方案。通过对符合临床病例定义的儿童鼻咽标本进行酶联免疫吸附试验来鉴定RSV抗原。
在5岁以下儿童中,印度尼西亚每1000儿童年RSV相关LRI的发病率为34例,尼日利亚为94例。每1000儿童年RSV相关严重LRI的发病率在莫桑比克为5例,在印度尼西亚为10例,在南非为9例。在所有研究点,大多数RSV病例发生在婴儿中。
这些研究表明,RSV在四个发展中国家5岁以下儿童的LRI负担中占很大比例,但差异较大。这种差异的可能解释包括社会因素,如家庭规模和寻求医疗保健的模式;感染人类免疫缺陷病毒(HIV)的儿童比例;以及用于获取样本的临床定义差异。病例的年龄分布表明需要一种能在儿童生命早期提供保护的RSV疫苗。